Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Simplifying the approach to the management of dyslipidemia.

Gaziano JM, Gaziano TA.

JAMA. 2009 Nov 18;302(19):2148-9. doi: 10.1001/jama.2009.1685. No abstract available.

PMID:
19920241
2.

[Treatment of dyslipidemia in 2014: European versus American guidelines].

Radermecker RP.

Rev Med Suisse. 2014 Aug 27;10(439):1534-7. French.

PMID:
25272669
3.

Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.

Jialal I, Smith G.

Metab Syndr Relat Disord. 2012 Jun;10(3):159-60. doi: 10.1089/met.2012.1500. No abstract available.

PMID:
22568574
4.

Statin therapy: when to think twice.

Wahawisan J, Tovar JM, Granberry MC.

J Fam Pract. 2013 Dec;62(12):726-32. No abstract available.

PMID:
24340334
5.

[ESC/EAS Guidelines for the management of dyslipidaemias].

Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegría E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs RH, Kjekshus JK, Perrone Filardi P, Riccardi G, Storey RF, David W; Clinical Practice Guidelines Committee of the Spanish Society of Cardiology..

Rev Esp Cardiol. 2011 Dec;64(12):1168.e1-1168.e60. doi: 10.1016/j.recesp.2011.09.014. Review. Spanish. No abstract available.

6.

Drug therapy of diabetic dyslipidemia: do the statins suffice?

Mooradian AD.

Am J Ther. 2015 Jan-Feb;22(1):87-8. doi: 10.1097/MJT.0b013e318293b0f9. No abstract available.

PMID:
23728161
7.

[Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].

Pérez A.

Endocrinol Nutr. 2010 Dec;57(10):457-9. doi: 10.1016/j.endonu.2010.05.010. Spanish. No abstract available.

PMID:
20688585
8.

[The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].

Olsson AG.

Lakartidningen. 2011 Nov 23-29;108(47):2442-3. Swedish. No abstract available.

PMID:
22468387
9.

[Reasons for a combination].

Núñez-Cortés JM.

Clin Investig Arterioscler. 2014 Jul;26 Suppl 1:40-1. doi: 10.1016/S0214-9168(14)70026-9. Spanish. No abstract available.

PMID:
25043547
10.

Role of dyslipidemia in patients with chronic kidney disease.

Marino A, Tannock LR.

Postgrad Med. 2013 Jul;125(4):28-37. doi: 10.3810/pgm.2013.07.2676. Review. No abstract available.

PMID:
23842535
11.

Universal screening and drug treatment of dyslipidemia in children and adolescents.

Psaty BM, Rivara FP.

JAMA. 2012 Jan 18;307(3):257-8. doi: 10.1001/jama.2011.1916. No abstract available.

PMID:
22174386
12.

Additional insights on how best to utilize statins.

Feeman WE Jr.

J Fam Pract. 2014 Mar;63(3):128. No abstract available.

PMID:
24701605
13.

Commentary: Controversies in NICE guidance on lipid modification for the prevention of cardiovascular disease.

Cappuccio FP.

BMJ. 2008 May 31;336(7655):1248-9. doi: 10.1136/bmj.39580.424352.AD. No abstract available.

14.

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.

Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E.

Can J Cardiol. 2009 Oct;25(10):567-79. Review.

15.

From the editor: drugs, genes, and lipoproteins.

Brown WV.

J Clin Lipidol. 2014 Nov-Dec;8(6):529-30. doi: 10.1016/j.jacl.2014.09.012. No abstract available.

PMID:
25499933
16.

Impact of the new American and British guidelines on the management and treatment of dyslipidemia in a Spanish working population.

Brotons C, Calvo-Bonacho E, Moral I, García-Margallo MT, Cortés-Arcas MV, Puig M, Vázquez-Pirillo G, Ruilope LM.

Rev Esp Cardiol (Engl Ed). 2014 Nov;67(11):906-11. doi: 10.1016/j.rec.2014.06.018.

PMID:
25278212
17.

[Achievement of therapeutic objectives].

Mantilla T.

Clin Investig Arterioscler. 2014 Jul;26 Suppl 1:20-4. doi: 10.1016/S0214-9168(14)70022-1. Spanish.

PMID:
25043543
18.

Dyslipidaemia: cardiovascular prevention--end of the road for niacin?

Tuteja S, Rader DJ.

Nat Rev Endocrinol. 2014 Nov;10(11):646-7. doi: 10.1038/nrendo.2014.159.

PMID:
25178730
19.

Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance.

Cooper A, O'Flynn N; Guideline Development Group..

BMJ. 2008 May 31;336(7655):1246-8. doi: 10.1136/bmj.39554.624086.AD. Review. No abstract available. Erratum in: BMJ. 2014;349:4718.

20.

[Multimodal therapy of dyslipidemia].

Stahn A, Hanefeld M.

Clin Res Cardiol Suppl. 2011 May;6:10-6. Review. German.

PMID:
22528173
Items per page

Supplemental Content

Support Center